How a medicine makes dangerous artery plaques safer
Atorvastatin Improves Plaque Stability in ApoE-Knockout Mice by Regulating Chemokines and Chemokine Receptors
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This medicine doesn't shrink the plaque, but it makes it less likely to burst by calming down inflammation and strengthening the plaque's outer layer.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 514 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This medicine doesn't shrink the plaque, but it makes it less likely to burst by calming down inflammation and strengthening the plaque's outer layer.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 514 / 72
Evidence Score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Publication
Authors
Nie P, Li D, Hu L, Jin S, Yu Y, Cai Z, Shao Q, Shen J, Yi J, Xiao H, Shen L, He B
Related Content
Claims (6)
Statins do not induce significant regression of established atherosclerotic plaque but reduce plaque progression and enhance plaque stability by lowering LDL cholesterol exposure to arterial walls.
In mice prone to clogged arteries, a daily dose of atorvastatin made the dangerous, rupture-prone plaques much less common—even though the overall blockage didn’t get smaller.
The drug lowered levels of two key inflammation signals in the blood, showing it reduces body-wide inflammation even when cholesterol doesn’t change.
The drug reduced the number of inflammatory immune cells inside the artery plaques by nearly 40%, which also made the plaques less fatty and changed their collagen structure.
The drug lowered the levels of chemical signals (MCP-1 and CX3CL1) that attract immune cells to plaques, and also reduced the number of receptors on blood cells that respond to those signals.